Ticagrelor With or Without Aspirin in High-Risk Patients With Anemia Undergoing Percutaneous Coronary Intervention: a subgroup analysis of the TWILIGHT trial.
Alessandro SpiritoAdnan KastratiDavide CaoUsman BaberSamantha SartoriDominick J AngiolilloCarlo BriguoriDavid J CohenGeorge DangasDariusz DudekJavier EscanedC Michael GibsonZhongjie ZhangVijay KunadianUpendra KaulRan KornowskiVijay KunadianYa-Ling HanShamir R MehtaGennaro SardellaSamin SharmaRichard A ShlofmitzBirgit VogelStuart J PocockStuart PocockRoxana MehranPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
In high-risk patients undergoing PCI, ticagrelor monotherapy after 3 months of ticagrelor-based DAPT was associated with a reduced risk of clinically relevant bleeding without any increase in ischemic events irrespective of anemia status. (TWILIGHT: NCT02270242).
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- patients undergoing
- coronary artery disease
- atrial fibrillation
- coronary artery bypass grafting
- chronic kidney disease
- phase iii
- iron deficiency
- open label
- coronary artery bypass
- clinical trial
- study protocol
- low dose
- phase ii
- combination therapy
- cardiovascular events
- heart failure
- type diabetes
- randomized controlled trial
- cardiovascular disease